Aethlon Medical told shareholders in June that it might not survive the next twelve months without new financing. In September, its stock gained more in a single premarket session than most small caps move in a year, on news that had nothing to do with anything Aethlon found in its own lab. A Yukon copper belt that last produced ore in 1982 turned up some of its highest grades yet, from ground an induced-polarization survey pointed at rather than a resurveyed old shaft. A GPU landlord that used to run a cancer-diagnostics lab finished shedding it this month.
Biotech & Life Sciences
Aethlon Medical Reverses Into a $180 Million Bet on Atopic Dermatitis, Stock Surges 374%
Aethlon Medical (Nasdaq: AEMD) announced a definitive merger agreement on September 17 with privately held North Immunology, Inc., structured as an all-stock reverse merger through two subsidiaries, Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC. The deal arrived alongside an oversubscribed $180 million private placement led by Bain Capital Life Sciences and Janus Henderson, expected to fund the combined company into the second half of 2028. Aethlon shares, which had been trading around $1.93, spiked as much as 471% in premarket trading and closed the session up 374% at $6.78, on volume of roughly 78 million shares.
North Immunology’s lead program, NOR-101, is a half-life extended bispecific antibody targeting both IL-13 and IL-18, aimed at atopic dermatitis and other immune and inflammatory diseases. There is no clinical data yet. Phase 1a dosing is not expected to begin until the first quarter of 2027, with interim safety and pharmacokinetic data due by mid-2027 and Phase 1b/2b topline results not expected until 2028.
The mechanics matter more than the headline number. This is a reverse merger, not an acquisition: Aethlon supplies the Nasdaq listing shell, and North Immunology ends up as the operating business inside a renamed public company. Post-closing, North Immunology’s shareholders and the PIPE participants are expected to hold approximately 95% of the combined entity, with Aethlon’s existing shareholders diluted to roughly 4.75%. Aethlon’s own hemofiltration device program, in development for more than a decade, becomes a minority piece of a company now organized around a preclinical dermatology asset. Aethlon disclosed substantial doubt about its ability to continue as a going concern in its annual report filed June 10, 2026; the merger effectively resolves that by replacing Aethlon’s balance sheet with North Immunology’s. The transaction still requires Aethlon shareholder approval and an effective SEC registration statement before it closes, and the combined company is expected to adopt a new ticker symbol on Nasdaq.
Mining & Minerals
Gladiator Metals Extends High-Grade Copper-Gold-Silver Zone at Cub East to 350 Meters of Strike
Gladiator Metals Corp. (TSXV: GLAD, OTCQX: GDTRF) reported further assay results on September 15 from the Cub East target at its Whitehorse Copper Project in the Yukon. Hole BCG-045 returned 21.2 meters at 3.07% copper, 1.19 g/t gold and 24.65 g/t silver from 183 meters depth. Hole BCG-050 returned 47 meters at 1.01% copper, 0.44 g/t gold and 7.07 g/t silver from 200 meters, including a higher-grade 32.31-meter interval at 1.40% copper. Fifteen additional holes reported similar stacked mineralization across the target.
The company says the high-grade core at Cub East is now confirmed over 350 meters of strike within a broader 1.5-kilometer geophysical trend, and step-out drilling 600 meters to the southeast has intersected additional skarn (mineralized rock formed where a molten intrusion reacts with carbonate rock), with assays still pending. Gladiator’s own release notes that the reported intervals are downhole widths, not true widths, because the geometry of the skarn contact is complex and variably oriented. No resource estimate currently exists for Cub East; the company is separately targeting a maiden NI 43-101 inferred resource at its nearby Cowley zone later in 2026, but that timeline does not apply to Cub East. Whitehorse Copper was a past producer between 1967 and 1982 under Hudson Bay Mining and Smelting.
Gladiator’s market capitalization stood at roughly $180 million as of the September 15 release, comfortably under the small-cap threshold, and OTCQX-listed GDTRF shares are DTC eligible. The company has expanded its planned 2026 drilling across Whitehorse Copper to more than 50,000 meters, with five rigs scheduled to be active in the fourth quarter.
Tech & Innovation
Axe Compute Finishes Its Pivot From Cancer Diagnostics to GPU Infrastructure
Axe Compute Inc. (Nasdaq: AGPU), formerly known as Predictive Oncology, completed the sale of its legacy Helomics Corporation cancer-diagnostics laboratory business to DataMEDS AI, Inc. (Nasdaq: MEDS) on September 15, in an all-stock transaction. Axe Compute received 636,328 shares of DataMEDS common stock, roughly a fifth of DataMEDS’ pre-closing share count, plus a $1.4 million convertible promissory note, for a deal valued at about $1.5 million. Both the shares and the note are subject to a 12-month lock-up. Axe Compute retains the base-rent obligation on Helomics’ former lab premises, a residual liability tied to the business it just sold.
The sale closes out a multi-year identity change. Axe Compute now describes itself as a neocloud AI infrastructure provider, delivering bare-metal GPU access through its relationship with the Aethir network rather than operating an oncology lab. The stock has been extremely volatile through the transition, trading anywhere from the single digits to well above $10 over the past year on thin average volume; investors weighing the pivot are effectively pricing an early-stage GPU-hosting business rather than the diagnostics company Axe Compute used to be. For DataMEDS, the deal adds a CLIA/CAP-certified clinical lab and a contract-research central-lab business to a company that already operates as a health IT and data-acquisition platform.
Green Energy & Cleantech: What Moved the Sector This Week
Lithium prices whipsawed this week after a data revision did more damage than any new mine. On September 8, a Chinese data provider revised its national lithium inventory estimate from 78,800 tonnes to 175,000 tonnes, and Chinese lithium carbonate futures fell more than 14% over the following three trading days, closing September 11 at 134,800 yuan a tonne, roughly $20,100, down 5% for the week. Large producers dropped alongside it: Albemarle lost 6.9% for the week and SQM lost 8.6%. Sigma Lithium was hit hardest, closing at $9.50 after a 23% weekly decline, compounded by a Brazilian federal judge suspending environmental licenses at its Grota do Cirilo mine in Minas Gerais, the third such halt in four months, after a Quilombola community federation argued the mine sits inside a legally protected consultation zone.
By September 18, Chinese lithium carbonate spot prices had fallen further, to about 143,000 yuan a tonne, the lowest in nearly a month, as the market weighed rising Australian supply against continued disruption in China. Mineral Resources restarted its Bald Hill mine after an 18-month suspension and Core Lithium restarted its Finniss project, adding supply just as CATL’s Jianxiawo mine, one of China’s largest by capacity, remained shut after Chinese authorities revoked its environmental approvals.
None of this activity was concentrated in a dedicated small or micro-cap TSX or CSE cleantech story this week; the moves played out at the large-cap producer and futures-market level, with names like Albemarle, SQM, Sigma Lithium and Mineral Resources named here only as examples of the broader trend.
Crypto & Fintech: What Moved the Sector This Week
Bitcoin fell toward $76,000 after the US Senate voted down a motion to advance the CLARITY Act, digital-asset market-structure legislation, on September 15, and the Federal Reserve raised interest rates by 25 basis points the following day. US spot Bitcoin ETFs booked two of their heaviest outflow days of the year, losing $450.4 million on September 15 and $295.9 million on September 16. The Securities and Exchange Commission responded on September 17 with a conditional exemption allowing certain tokenized stocks to trade on blockchains for the next five years.
Bitcoin bottomed near $76,400 on September 17, and a short squeeze then drove a rebound to $81,702 by September 18, with roughly $300 million of leveraged short positions liquidated within four hours. ETF flows reversed too, with $159.5 million of net inflows on September 17 and $433 million on September 18, led by Fidelity’s FBTC and BlackRock’s IBIT. By Saturday, September 19, bitcoin was trading around $81,000 to $81,900, up about 3.4% for the month despite the midweek dip. Because much of the bounce came from short covering rather than new buying, and because Federal Reserve officials’ own projections show 12 of 18 expecting at least one more rate hike before year-end, the rebound’s durability is not yet confirmed.
None of this activity was concentrated in small or micro-cap crypto or fintech equities on the TSX or CSE this week; the swings played out entirely at the token and ETF level.
What to Watch Next
Aethlon shareholders still need to approve the deal and the SEC registration statement covering the merger shares needs to become effective. Assuming both happen, the first clinical readout is still more than a year away: interim Phase 1a safety and pharmacokinetic data for NOR-101 isn’t expected until mid-2027.
Assays are pending for the step-out holes 600 meters to the southeast and for two holes testing whether the mineralized zone connects to the historic Black Cub South open pit. Gladiator has also raised its 2026 Whitehorse Copper drill program to more than 50,000 meters, with five rigs scheduled for the fourth quarter.
With the divestiture complete, Axe Compute is a pure-play neocloud GPU-as-a-service provider built on the Aethir network. The next test is whether GPU-hosting revenue can outrun the cash burn that has made the stock swing from the single digits to well above $10 and back over the past year.
That depends on whether China’s revised stockpile figures hold up under scrutiny and how quickly Mineral Resources’ and Core Lithium’s restarted mines actually ship material. A resolution of the CATL Jianxiawo permitting dispute, in either direction, could move prices sharply from here.
The rebound off the midweek low leaned heavily on short covering rather than fresh buying, so the next two weeks of ETF flow data will show whether new demand actually followed it, ahead of the Fed’s next meeting in late October.
Sources
- Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis, PRNewswire, September 17, 2026
- Aethlon Medical (AEMD) Stock Explodes 471% Following North Immunology Merger Announcement, Parameter, September 17, 2026
- Aethlon Medical, Inc. Form 10-K for fiscal year ended March 31, 2026, filed with SEC EDGAR, June 10, 2026
- Gladiator Intersects 21.2m @ 3.07% Cu + 1.19 g/t Au at Cub East, Expanding High-Impact Discovery, StockTitan / Newsfile Corp, September 15, 2026
- Axe Compute Sells Helomics AI Cancer Diagnostics Lab Business to DataMEDS AI, GlobeNewswire, September 15, 2026
- Axe Compute Finalizes Helomics Divestiture; Receives 20% Stake in DataMeds, Panabee, September 2026
- Lithium Slides as a Data Revision Doubles China’s Stockpiles, Rio Times, September 14, 2026
- Lithium historical price and market commentary, Trading Economics, accessed September 20, 2026
- September Is Bitcoin’s Worst Month and It’s Up 2.7% So Far. What That Says About Q4, 24/7 Wall St., September 19, 2026
- Bitcoin Is Back at $80,000 as Rest of Crypto Joins the Rally: Chart of the Day, Yahoo Finance, September 19, 2026
Editorial Disclosure
The Green Energy & Cleantech and Crypto & Fintech items in this article cover sector-wide activity; no specific company is the subject of coverage in either. Tickers discussed as company subjects in this article: AEMD (Aethlon Medical, entering a reverse merger with North Immunology, Inc. and expected to adopt a new ticker on closing), GLAD / GDTRF (Gladiator Metals Corp.), and AGPU (Axe Compute Inc.); DataMEDS AI, Inc. (MEDS) is named as a transaction counterparty rather than a subject of dedicated coverage. aktiego.com has received no compensation from any company, IR firm, or third party in connection with this coverage, and no aktiego.com staff member holds a position in any security named above. Press release dates and primary sources were verified against company investor-relations pages, PRNewswire, GlobeNewswire, Newsfile Corp, and SEC EDGAR where applicable. All companies named as subjects are under $500 million USD in market capitalization as of the dates referenced above; large-cap and mid-cap names appearing in the Green Energy & Cleantech and Crypto & Fintech sections (including Albemarle, SQM, Sigma Lithium, Mineral Resources, Core Lithium and CATL) are named only as examples of sector-wide activity and are not subjects of this coverage. Aethlon Medical’s merger with North Immunology, Inc. is a reverse merger: on closing, North Immunology’s shareholders and the concurrent $180 million private placement’s participants are expected to hold approximately 95% of the combined company, with Aethlon’s existing shareholders diluted to approximately 4.75%, and the transaction remains subject to Aethlon shareholder approval and SEC registration effectiveness. Aethlon disclosed substantial doubt about its ability to continue as a going concern in its annual report filed June 10, 2026. North Immunology’s lead program, NOR-101, is preclinical, with no human dosing expected before the first quarter of 2027. Gladiator Metals Corp. reports its Cub East intervals as downhole widths rather than true widths, and no NI 43-101 (the Canadian regulatory standard governing disclosure of mineral project results) compliant resource estimate currently exists for the Cub East target. Axe Compute Inc. retains a residual lease-rent liability on the Helomics premises it divested, and its shares have traded at highly volatile, thinly-traded valuations over the past year. These are speculative investments carrying significant risk including potential total loss of capital. Digital assets are highly volatile. Coverage on aktiego.com is provided for informational and educational purposes only, aktiego.com is not a registered investment advisor, and nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
